Indonesia’s pharmaceutical giant, Kalbe Farma (KLBF), has unveiled its financial performance for the second quarter of 2025 (2Q25), presenting a nuanced picture for investors. While the company’s bottom line saw a significant boost, a closer look reveals underlying operational pressures that merit attention.

Robust Net Profit Outpaces Expectations

KLBF reported a commendable net profit of IDR 898 billion in 2Q25, marking a solid +6% year-over-year (YoY) growth. Despite a sequential dip of -17% quarter-over-quarter (QoQ), this strong Q2 showing propelled the first half of 2025 (1H25) net profit to an impressive IDR 1.98 trillion, representing a +9% YoY increase. This 1H25 performance aligns seamlessly with market expectations, achieving 56% of the 2025F consensus estimate, comfortably above the two-year average annual realization of 55%.

Operational Performance: A Softer Trajectory

Slower Growth in Q2 Operations

Delving deeper into the operational aspects, KLBF experienced a notable slowdown in 2Q25. Operating profit saw a slight decline of -1% YoY in 2Q25, a stark contrast to the robust +13% YoY growth recorded in 1Q25. Consequently, 1H25 operating profit growth moderated to +7% YoY. This deceleration stems from a milder revenue expansion of just +3% YoY in 2Q25 (down from +6% YoY in 1Q25) and a noticeable contraction in the operating profit margin.

Margin Squeeze: The Impact of Selling Expenses

The company’s operating profit margin receded to 12.9% in 2Q25, a significant step down from 15.6% in 1Q25 and 13.5% in 2Q24. The primary culprit behind this margin compression was a substantial +13% YoY surge in selling expenses. A key component of this increase was heightened spending on advertising and promotion (A&P), a strategic investment that weighed on immediate profitability.

The Unseen Catalyst: Non-Operating Income Bolsters the Bottom Line

Interestingly, KLBF’s 2Q25 net profit received a crucial uplift from non-operating income. Gains, primarily stemming from the sale of fixed assets, provided a significant boost. This additional income stream allowed net profit growth to outpace the more modest operating profit growth in the quarter, acting as a valuable cushion amidst the operational slowdown.

Investor Outlook: Balancing Growth and Investment

Kalbe Farma’s latest report paints a picture of a company investing in its future while navigating a dynamic market. While robust net profit growth, bolstered by opportunistic asset sales, provides a reassuring headline, investors will be closely monitoring the trend in operational efficiency and the impact of continued marketing investments. The balance between short-term margin pressures and long-term market penetration remains a key narrative for KLBF as it moves forward.